Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | PLAU | P00749 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626660 | 1.00 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8216089 | 0.84 | ELANE (0.52) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5822952 | 0.82 | MAP2K4 (0.47) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30438051 | 0.82 | MAP2K4 (0.47) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2674135 | 0.82 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7016168 | 0.82 | L3MBTL1 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL28157040 | 0.82 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14739081 | 0.82 | HTR6 (0.46) | MAP2K4KDM4EALDH1A1ELANEGABRG2 | |
| SCHEMBL177566 | 0.82 | ESR2 (0.40) | MAP2K4KDM4EALDH1A1ELANEGABRG2 | |
| SCHEMBL30343304 | 0.82 | GABRG2 (0.38) | MAP2K4KDM4EALDH1A1BCHEELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117430589-A | 2-aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | NORTHWESTERN UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1648448-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011681-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | MAP2K4 895/4885CHRM2 2474/4885CHRM4 3214/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | MAP2K4 4302/4885CHRM2 4029/4885CHRM4 4657/4885 |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | FLT4, KDR, CYP3A4 | MAP2K4 1032/4885CHRM2 53/4885CHRM4 12/4885 |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | MAP2K4 2669/4885CHRM2 3288/4885CHRM4 3711/4885 |
| US-20080058515-A1 | Chemical Compounds | SGK1, SGK2, SGK3 | MAP2K4 559/4885CHRM2 4694/4885CHRM4 4760/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | MAP2K4 72/4885CHRM2 4791/4885CHRM4 4771/4885 |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885CHRM2 4780/4885CHRM4 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.